Abstract: IDO1, a key dioxygenase in tryptophan-kynurenine metabolism, appeared in the last 10 years at the vanguard of druggable targets in cancer therapy due to its well-established role both in immune escape and inflammatory neovascularization. Among the pool of IDO1 inhibitors that have entered clinical trials, none have reached approval. The identification of novel inhibitors endowed with better clinical profile, together with the further comprehension of the interactions with residues in IDO1 active site, are still a need. In this context, we have synthesized a novel class of imidazothiazole derivatives as IDO1 inhibitors and identified three compounds with inhibitory potency in the low micromolar range. This report strengthens the role played by pocket C in the active site of IDO1, providing novel directions in the design of IDO1 inhibitors.
Introduction
The tryptophan to kynurenine catabolism and the dioxygenases that catalyse the first and rate-limiting step along the kynurenine pathway play a crucial role in the pathological immune escape [1] [2] [3] . Depletion of tryptophan and the consequent increase in kynurenines in the tumour microenvironment have been shown to enhance inflammation and lead to an immune-permissive milieu [4] as well as to promote neo-angiogenesis [5] . Among the three different isoforms of dioxygenases, IDO1, IDO2 and TDO, the former has appeared at centre-stage in the cancer field with hundreds of IDO1 inhibitors discovered in the past [6] .
In the last decades checkpoint inhibitors (i.e., anti PD-1/PD-L1) have revolutionized the scenario of cancer immunotherapy [7] . Nevertheless, it is becoming apparent that molecules able to boost the effects of cancer immunotherapy can potentially provide superior response rates, considering that a significant proportion of patients do not respond to these drugs. Great hopes have been placed on IDO1 inhibitors with five different molecules (indoximod, navoximod, epacadostat, BMS-986205, PF-06840003) that have entered clinical trials. Currently, navoximod and PF-06840003 are in Phase I trials, while indoximod, BMS-986205 and epacadostat have reached Phase III trials for the treatment of different types of cancers (e.g., melanoma, solid tumors, malignant glioma) [6] .
In 2018 the report at the ASCO Annual Meeting that epacadostat failed to show a clinical benefit in combination to pembrolizumab in unresectable or metastatic melanoma suggested to reconsider if some elements have been neglected in IDO1 landscape [8] . From a clinical point of view, the best combination regimen, the most responsive patients and the biomarkers that allow to identify them, and the most responsive tumor settings still need to be identified [9] . Additional efforts in the IDO1 field are required even from a medicinal chemistry point of view. A major challenge is the discovery of IDO1 inhibitors with optimal profiles for clinical development, especially in relation to achievement of bioavailability, maintenance of inhibition levels in vivo, crossing of the BBB to target brain metastases, and in-depth functional characterization. Moreover, the correlation between inhibition kinetics and in vivo antitumor activity is still not clear and the data that will arise during clinical trials will help to clarify if it is more effective a competitive, a non-competitive or an irreversible inhibitor. Finally, a better comprehension of the possible interactions with the residues in the IDO1 active site is needed in order to guide the rational design of other novel and potent IDO1 inhibitors.
Results

Chemistry
In 2014, imidazothiazole compounds were reported by Tojo et al. as potent IDO1 inhibitors, with the reference compound 1 ( Figure 1 ) displaying an IC 50 value of 1.9 µM (rhIDO1) [10] . Taking advantage of our extensive experience both in multicomponent reactions [11, 12] and click chemistry approach [13] , as well as their exploitation in drug discovery [14] [15] [16] [17] , we decided to synthesize in parallel two series of imidazothiazole analogues.
The first series, published in 2018 [18] , was obtained using Passerini three-component and Ugi four-component reactions. The most potent compounds are represented by 2 and 3 ( Figure 1 ) with IC 50 values of 0.20 µM and 0.80 µM, respectively. Docking studies have suggested the ability of the imidazole nitrogen to coordinate the iron moiety in the heme group ( Figure 2) . Furthermore, the long chain protrudes in a region, named pocket C, which has never been considered by previous IDO inhibitors and a crucial hydrogen bond with Lys238 favours the inhibitory activity.
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From a clinical point of view, the best combination regimen, the most responsive patients and the biomarkers that allow to identify them, and the most responsive tumor settings still need to be identified [9] . Additional efforts in the IDO1 field are required even from a medicinal chemistry point of view. A major challenge is the discovery of IDO1 inhibitors with optimal profiles for clinical development, especially in relation to achievement of bioavailability, maintenance of inhibition levels in vivo, crossing of the BBB to target brain metastases, and in-depth functional characterization. Moreover, the correlation between inhibition kinetics and in vivo antitumor activity is still not clear and the data that will arise during clinical trials will help to clarify if it is more effective a competitive, a non-competitive or an irreversible inhibitor. Finally, a better comprehension of the possible interactions with the residues in the IDO1 active site is needed in order to guide the rational design of other novel and potent IDO1 inhibitors.
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In 2014, imidazothiazole compounds were reported by Tojo et al. as potent IDO1 inhibitors, with the reference compound 1 ( Figure 1 ) displaying an IC50 value of 1.9 µM (rhIDO1) [10] . Taking advantage of our extensive experience both in multicomponent reactions [11, 12] and click chemistry approach [13] , as well as their exploitation in drug discovery [14] [15] [16] [17] , we decided to synthesize in parallel two series of imidazothiazole analogues.
The first series, published in 2018 [18] , was obtained using Passerini three-component and Ugi four-component reactions. The most potent compounds are represented by 2 and 3 ( Figure 1 ) with IC50 values of 0.20 µM and 0.80 µM, respectively. Docking studies have suggested the ability of the imidazole nitrogen to coordinate the iron moiety in the heme group (Figure 2) . Furthermore, the long chain protrudes in a region, named pocket C, which has never been considered by previous IDO inhibitors and a crucial hydrogen bond with Lys238 favours the inhibitory activity. From a clinical point of view, the best combination regimen, the most responsive patients and the biomarkers that allow to identify them, and the most responsive tumor settings still need to be identified [9] . Additional efforts in the IDO1 field are required even from a medicinal chemistry point of view. A major challenge is the discovery of IDO1 inhibitors with optimal profiles for clinical development, especially in relation to achievement of bioavailability, maintenance of inhibition levels in vivo, crossing of the BBB to target brain metastases, and in-depth functional characterization. Moreover, the correlation between inhibition kinetics and in vivo antitumor activity is still not clear and the data that will arise during clinical trials will help to clarify if it is more effective a competitive, a non-competitive or an irreversible inhibitor. Finally, a better comprehension of the possible interactions with the residues in the IDO1 active site is needed in order to guide the rational design of other novel and potent IDO1 inhibitors.
Results
Chemistry
In 2014, imidazothiazole compounds were reported by Tojo et al. as potent IDO1 inhibitors, with the reference compound 1 (Figure 1 ) displaying an IC50 value of 1.9 µM (rhIDO1) [10] . Taking advantage of our extensive experience both in multicomponent reactions [11, 12] and click chemistry approach [13] , as well as their exploitation in drug discovery [14] [15] [16] [17] , we decided to synthesize in parallel two series of imidazothiazole analogues.
The first series, published in 2018 [18] , was obtained using Passerini three-component and Ugi four-component reactions. The most potent compounds are represented by 2 and 3 ( Figure 1 ) with IC50 values of 0.20 µM and 0.80 µM, respectively. Docking studies have suggested the ability of the imidazole nitrogen to coordinate the iron moiety in the heme group (Figure 2) . Furthermore, the long chain protrudes in a region, named pocket C, which has never been considered by previous IDO inhibitors and a crucial hydrogen bond with Lys238 favours the inhibitory activity. In the meanwhile, we wondered whether the benzylamide moiety, represented by compounds 2 and 3, could be isosterically replaced by a 1,4-disubstitued 1,2,3-triazole ring. It must be acknowledged that the triazole moiety has been previously described by Röhrig et al. [19] in IDO1 inhibitors and, more recently, in inhibitors selective for IDO2 [20] . In 2018 other triazole-displaying IDO1 inhibitors were reported [21] . In all the described examples, the nitrogen of the triazole ring makes a bond with the iron of the heme group.
With the aim to further probe interactions of the side chain of imidazothiazoles with the active site of IDO1 enzyme, and especially with pocket C, we synthesized two classes of imidazothiazoles, the first one starting from azide 8 and the second from azide 10 (Scheme 1).
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In the meanwhile, we wondered whether the benzylamide moiety, represented by compounds 2 and 3, could be isosterically replaced by a 1,4-disubstitued 1,2,3-triazole ring. It must be acknowledged that the triazole moiety has been previously described by Röhrig et al. [19] in IDO1 inhibitors and, more recently, in inhibitors selective for IDO2 [20] . In 2018 other triazole-displaying IDO1 inhibitors were reported [21] . In all the described examples, the nitrogen of the triazole ring makes a bond with the iron of the heme group.
With the aim to further probe interactions of the side chain of imidazothiazoles with the active site of IDO1 enzyme, and especially with pocket C, we synthesized two classes of imidazothiazoles, the first one starting from azide 8 and the second from azide 10 (Scheme 1). Both the imidazothiazole azides can be easily obtained by exploiting a common synthetic route starting from 4-(4-bromophenyl)thiazol-2-amine (4) that reacts with DMF-DMA and with ethyl bromoacetate to afford intermediate 5. Compound 5 undergoes an intramolecular cyclization and a reduction to yield compound 7 that reacts in the presence of DPPA to form the required azide 8. The latter is reduced via a Staudinger reaction and then compound 9 is coupled with 2-azidoacetic acid to form azide 10 (Scheme 1).
With the aim to maximize the interaction of the products in IDO1 active site, the synthetic effort was in silico-guided. To this end, alkynes purchasable and/or previously synthesized in our lab were virtually combined with azides 8 and 10 to generate a small library of 88 candidates that were screened in the IDO1 active site. The compounds were then ranked according to their binding energies in the IDO1 protein and the virtual candidates displaying the highest score per each of the two classes were inspected. Finally, the corresponding alkyne was selected for being coupled with both the azides 8 and 10, for reasons of systematicity and completeness.
Following this approach, 11 alkynes were chosen, and 22 compounds were prepared exploiting the click chemistry reaction under classical conditions, eleven (11a-11k) from azide 8 and eleven (12a-12k) from azide 10. Products precipitated from the reaction mixture and, after filtration, were purified by column chromatography.
Biological Evaluation
All the 22 synthesized compounds were then biologically evaluated ( Table 1 ). The compounds were tested for their ability to inhibit human IDO1 in an enzyme-based assay using a purified recombinant human IDO1 (rhIDO1) enzyme (Table 1 ). Each compound (1 µM) was added to the reaction buffer and the rhIDO1 conversion of L-Trp to L-KYN was determined spectrophotometrically using p-dimethylaminobenzaldehyde. As reference, imidazothiazole compound 1-((3-(4-bromophenyl)-3aH-thieno [2,3-b] pyrrol-4-yl)methyl)-3-(4-cyanophenyl)urea [10] , displaying an IC50 value of 0.08 µM, was chosen. Both the imidazothiazole azides can be easily obtained by exploiting a common synthetic route starting from 4-(4-bromophenyl)thiazol-2-amine (4) that reacts with DMF-DMA and with ethyl bromoacetate to afford intermediate 5. Compound 5 undergoes an intramolecular cyclization and a reduction to yield compound 7 that reacts in the presence of DPPA to form the required azide 8. The latter is reduced via a Staudinger reaction and then compound 9 is coupled with 2-azidoacetic acid to form azide 10 (Scheme 1).
All the 22 synthesized compounds were then biologically evaluated ( Table 1 ). The compounds were tested for their ability to inhibit human IDO1 in an enzyme-based assay using a purified recombinant human IDO1 (rhIDO1) enzyme (Table 1 ). Each compound (1 µM) was added to the reaction buffer and the rhIDO1 conversion of l-Trp to l-KYN was determined spectrophotometrically using p-dimethylaminobenzaldehyde.
As reference, imidazothiazole compound 1-((3-(4-bromophenyl)-3aH-thieno [2,3-b] pyrrol-4-yl)methyl)-3-(4-cyanophenyl)urea [10] , displaying an IC 50 value of 0.08 µM, was chosen. In series 11a-11k, among the aromatic substituents on the triazole ring only cyanomethylphenyl ring confers significant inhibitory activity at 1 µM (11f, 74%), while within the aliphatic substructures both the propanoyl and the 5-cyanopentanoyl lead to good inhibition (11j and 11k, 81 and 62%, respectively). In series 12a-12k the best activity is given by the cyclopropyl substituent (12g, 70%), while benzyl and 1-hydroxycyclohexanyl (12a and 12h) are able to give a 63% of inhibition.
IC50 values were determined for compounds that displayed an inhibition above 70% (11f, 11j and 12g). Compound 11f has an IC50 value of 0.5 ± 0.04 µM, 11j displays IC50 value of 1.1 ± 0.07 µM and compound 12g of 0.2 ± 0.01 µM.
Molecular Docking Study
Molecular modelling was exploited to understand the potential pose of imidazothiazoles in the IDO1 binding site. Docking studies were carried out using the software OMEGA2 [22] [23] [24] and FRED [25, 26] , showing that the most potent imidazothiazoles (11f and 12g) ( Figure 3 ) lay with a partially different orientation than compounds 2 and 3 ( Figure 2 ). The p-bromophenyl ring of both 11f and 12g is accommodated in the hydrophobic pocket A (Tyr126, Cys129, Val130, Phe163 and Phe164), as for compounds 2 and 3, while the imidazothiazole core is able to form a nitrogen-iron bond with the heme group. The triazole group extends in proximity to pocket B (Phe226 and Arg231) while the side chain derived by alkyne reagent protrudes in the direction of pocket C (Leu234, Ser235, Gly236, Lys238, Ala260, Gly261 and Gly262), without fully occupying this external part of the IDO binding site as shown by 2 and 3. All the other compounds display similar binding modes (Supporting In series 11a-11k, among the aromatic substituents on the triazole ring only cyanomethylphenyl ring confers significant inhibitory activity at 1 µM (11f, 74%), while within the aliphatic substructures both the propanoyl and the 5-cyanopentanoyl lead to good inhibition (11j and 11k, 81 and 62%, respectively). In series 12a-12k the best activity is given by the cyclopropyl substituent (12g, 70%), while benzyl and 1-hydroxycyclohexanyl (12a and 12h) are able to give a 63% of inhibition.
Molecular modelling was exploited to understand the potential pose of imidazothiazoles in the IDO1 binding site. Docking studies were carried out using the software OMEGA2 [22] [23] [24] and FRED [25, 26] , showing that the most potent imidazothiazoles (11f and 12g) ( Figure 3) lay with a partially different orientation than compounds 2 and 3 ( Figure 2 ). The p-bromophenyl ring of both 11f and 12g is accommodated in the hydrophobic pocket A (Tyr126, Cys129, Val130, Phe163 and Phe164), as for compounds 2 and 3, while the imidazothiazole core is able to form a nitrogen-iron bond with the heme group. The triazole group extends in proximity to pocket B (Phe226 and Arg231) while the side chain derived by alkyne reagent protrudes in the direction of pocket C (Leu234, Ser235, Gly236, Lys238, Ala260, Gly261 and Gly262), without fully occupying this external part of the IDO binding site as shown by 2 and 3. All the other compounds display similar binding modes (Supporting In series 11a-11k, among the aromatic substituents on the triazole ring only cyanomethylphenyl ring confers significant inhibitory activity at 1 µM (11f, 74%), while within the aliphatic substructures both the propanoyl and the 5-cyanopentanoyl lead to good inhibition (11j and 11k, 81 and 62%, respectively). In series 12a-12k the best activity is given by the cyclopropyl substituent (12g, 70%), while benzyl and 1-hydroxycyclohexanyl (12a and 12h) are able to give a 63% of inhibition.
Molecular modelling was exploited to understand the potential pose of imidazothiazoles in the IDO1 binding site. Docking studies were carried out using the software OMEGA2 [22] [23] [24] and FRED [25, 26] , showing that the most potent imidazothiazoles (11f and 12g) ( Figure 3) lay with a partially different orientation than compounds 2 and 3 ( Figure 2 ). The p-bromophenyl ring of both 11f and 12g is accommodated in the hydrophobic pocket A (Tyr126, Cys129, Val130, Phe163 and Phe164), as for compounds 2 and 3, while the imidazothiazole core is able to form a nitrogen-iron bond with the heme group. The triazole group extends in proximity to pocket B (Phe226 and Arg231) while the side chain derived by alkyne reagent protrudes in the direction of pocket C (Leu234, Ser235, Gly236, Lys238, Ala260, Gly261 and Gly262), without fully occupying this external part of the IDO binding site as shown by 2 and 3. All the other compounds display similar binding modes (Supporting b In series 11a-11k, among the aromatic substituents on the triazole ring only cyanomethylphenyl ring confers significant inhibitory activity at 1 µM (11f, 74%), while within the aliphatic substructures both the propanoyl and the 5-cyanopentanoyl lead to good inhibition (11j and 11k, 81 and 62%, respectively). In series 12a-12k the best activity is given by the cyclopropyl substituent (12g, 70%), while benzyl and 1-hydroxycyclohexanyl (12a and 12h) are able to give a 63% of inhibition.
Molecular modelling was exploited to understand the potential pose of imidazothiazoles in the IDO1 binding site. Docking studies were carried out using the software OMEGA2 [22] [23] [24] and FRED [25, 26] , showing that the most potent imidazothiazoles (11f and 12g) ( Figure 3) lay with a partially different orientation than compounds 2 and 3 ( Figure 2 ). The p-bromophenyl ring of both 11f and 12g is accommodated in the hydrophobic pocket A (Tyr126, Cys129, Val130, Phe163 and Phe164), as for compounds 2 and 3, while the imidazothiazole core is able to form a nitrogen-iron bond with the heme group. The triazole group extends in proximity to pocket B (Phe226 and Arg231) while the side chain derived by alkyne reagent protrudes in the direction of pocket C (Leu234, Ser235, Gly236, Lys238, Ala260, Gly261 and Gly262), without fully occupying this external part of the IDO binding site as shown by 2 and 3. All the other compounds display similar binding modes (Supporting c In series 11a-11k, among the aromatic substituents on the triazole ring only cyanomethylphenyl ring confers significant inhibitory activity at 1 µM (11f, 74%), while within the aliphatic substructures both the propanoyl and the 5-cyanopentanoyl lead to good inhibition (11j and 11k, 81 and 62%, respectively). In series 12a-12k the best activity is given by the cyclopropyl substituent (12g, 70%), while benzyl and 1-hydroxycyclohexanyl (12a and 12h) are able to give a 63% of inhibition.
Molecular modelling was exploited to understand the potential pose of imidazothiazoles in the IDO1 binding site. Docking studies were carried out using the software OMEGA2 [22] [23] [24] and FRED [25, 26] , showing that the most potent imidazothiazoles (11f and 12g) ( Figure 3) lay with a partially different orientation than compounds 2 and 3 ( Figure 2 ). The p-bromophenyl ring of both 11f and 12g is accommodated in the hydrophobic pocket A (Tyr126, Cys129, Val130, Phe163 and Phe164), as for compounds 2 and 3, while the imidazothiazole core is able to form a nitrogen-iron bond with the heme group. The triazole group extends in proximity to pocket B (Phe226 and Arg231) while the side chain derived by alkyne reagent protrudes in the direction of pocket C (Leu234, Ser235, Gly236, Lys238, Ala260, Gly261 and Gly262), without fully occupying this external part of the IDO binding site as shown by 2 and 3. All the other compounds display similar binding modes (Supporting e 11e, 83% 28 ± 1.5 12e, 76% 50 ± 4.5
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Molecular modelling was exploited to understand the potential pose of imidazothiazoles in the IDO1 binding site. Docking studies were carried out using the software OMEGA2 [22] [23] [24] and FRED [25, 26] , showing that the most potent imidazothiazoles (11f and 12g) ( Figure 3) lay with a partially different orientation than compounds 2 and 3 ( Figure 2 ). The p-bromophenyl ring of both 11f and 12g is accommodated in the hydrophobic pocket A (Tyr126, Cys129, Val130, Phe163 and Phe164), as for compounds 2 and 3, while the imidazothiazole core is able to form a nitrogen-iron bond with the heme group. The triazole group extends in proximity to pocket B (Phe226 and Arg231) while the side chain derived by alkyne reagent protrudes in the direction of pocket C (Leu234, Ser235, Gly236, Lys238, Ala260, Gly261 and Gly262), without fully occupying this external part of the IDO binding site as shown by 2 and 3. All the other compounds display similar binding modes (Supporting j 11j, 41% 81 ± 7.9 12j, 42% 33 ± 4.5
Molecular modelling was exploited to understand the potential pose of imidazothiazoles in the IDO1 binding site. Docking studies were carried out using the software OMEGA2 [22] [23] [24] and FRED [25, 26] , showing that the most potent imidazothiazoles (11f and 12g) ( Figure 3) lay with a partially different orientation than compounds 2 and 3 ( Figure 2 ). The p-bromophenyl ring of both 11f and 12g is accommodated in the hydrophobic pocket A (Tyr126, Cys129, Val130, Phe163 and Phe164), as for compounds 2 and 3, while the imidazothiazole core is able to form a nitrogen-iron bond with the heme group. The triazole group extends in proximity to pocket B (Phe226 and Arg231) while the side chain derived by alkyne reagent protrudes in the direction of pocket C (Leu234, Ser235, Gly236, Lys238, Ala260, Gly261 and Gly262), without fully occupying this external part of the IDO binding site as shown by 2 and 3. All the other compounds display similar binding modes (Supporting k 11k, 48% 62 ± 5.6 12k, 55% 50 ± 11
a the values are the mean ± SE of two independent experiments.
In series 11a-11k, among the aromatic substituents on the triazole ring only cyanomethylphenyl ring confers significant inhibitory activity at 1 µM (11f, 74%), while within the aliphatic substructures both the propanoyl and the 5-cyanopentanoyl lead to good inhibition (11j and 11k, 81 and 62%, respectively). In series 12a-12k the best activity is given by the cyclopropyl substituent (12g, 70%), while benzyl and 1-hydroxycyclohexanyl (12a and 12h) are able to give a 63% of inhibition.
IC 50 values were determined for compounds that displayed an inhibition above 70% (11f, 11j and 12g). Compound 11f has an IC 50 value of 0.5 ± 0.04 µM, 11j displays IC 50 value of 1.1 ± 0.07 µM and compound 12g of 0.2 ± 0.01 µM.
Molecular modelling was exploited to understand the potential pose of imidazothiazoles in the IDO1 binding site. Docking studies were carried out using the software OMEGA2 [22] [23] [24] and FRED [25, 26] , showing that the most potent imidazothiazoles (11f and 12g) ( Figure 3) lay with a partially different orientation than compounds 2 and 3 ( Figure 2 ). The p-bromophenyl ring of both 11f and 12g is accommodated in the hydrophobic pocket A (Tyr126, Cys129, Val130, Phe163 and Phe164), as for compounds 2 and 3, while the imidazothiazole core is able to form a nitrogen-iron bond with the heme group. The triazole group extends in proximity to pocket B (Phe226 and Arg231) while the side chain derived by alkyne reagent protrudes in the direction of pocket C (Leu234, Ser235, Gly236, Lys238, Ala260, Gly261 and Gly262), without fully occupying this external part of the IDO binding site as shown by 2 and 3. All the other compounds display similar binding modes (Supporting information Table S1 ): the interactions in pocket A and B are conserved among all the evaluated structures, while binding to pocket C is more compound-dependent.
information Table S1 ): the interactions in pocket A and B are conserved among all the evaluated structures, while binding to pocket C is more compound-dependent. 
Materials and Methods
Chemistry
General Chemistry
Commercially available reagents and solvents were purchased from Merck (Darmstadt, Germany) and Alfa Aesar (Thermo-Fisher Scientific, Waltham, USA, MA) and used without further purification. To a suspension of azide (0.29 mmol, 1 equiv.) in water (570 µL) and t-BuOH (570 µL) alkyne (0.29 mmol, 1 equiv.) was added. Then, 30 µL of aqueous solution of sodium ascorbate 1 M and copper sulfate pentahydrate (0.0029 mmol, 0.01 eq) were added and the mixture was maintained under vigorous stirring overnight. The reaction was normally completed between 3 and 24 h. Ice was added and the precipitate was filtered and rinsed with water and heptane. In some cases (11a, 11e, 11g, 12a,  12b, 12d, 12e, 12f, 12g, 12i, 12j, 12k ) product precipitated and the precipitated solid was collected by filtration using a Buchner funnel and rinsed with ethyl acetate. In case that no precipitation was observed (11b, 11c, 11d, 11f, 11h, 11i, 11j, 11k, 12c, 12h ) solvent was evaporated and the crude material was purified by column chromatography using the eluent indicated in the analytical data section. [25, 26] . The center of the binding pocket considered in the study was set in the geometrical center of the original co-crystalized compound (1), standard setting of FRED was used and the Chemgauss4 scores were considered to evaluate the docking poses. The representation of protein structures and docking results were generated using PyMOL software (version 2.1, New York, NY, USA) [28] .
Conclusions
In conclusion, following a common synthetic route, two series of imidazothiazoles have been synthesized by a click chemistry approach. Three compounds show inhibitory activity on IDO1 in the enzyme-based assay in the low micromolar range. Compound 12g displays a ten-fold higher inhibitory activity (IC 50 = 0.2 µM) compared to the starting compound (IC 50 = 1.9 µM). Moreover, it is characterized by a peculiar binding mode that sees the side chain protruding into an additional pocket, named C and located in the most external part of the IDO binding site. Unfortunately, and similarly to what was observed in the case of imidazothiazoles reported by Tojo [10] and compounds 2 and 3 discovered in our laboratory [18] , these molecules are not able to significantly permeate the cell and to inhibit IDO1 in a cell-based assay (data not shown).
Overall, the information acquired both in this study and in our previous work [18] provides new insights in the field of IDO1 inhibitors. Indeed, we have demonstrated that pocket C can be exploited in the design of next generations of IDO1 inhibitors. The integration of this information in a structure-based virtual screening performed in our laboratory has recently led to the identification of structurally novel IDO1 inhibitors with cellular potency in the low nanomolar level and improved clinical potential. These further studies will be reported in due course.
Supplementary Materials: The following are available online. Table S1 : Structure and biological profile of compounds evaluated by molecular docking.
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